7 min. Read

Oura subscription revs, rings sold, hardware margin. New ACCESS Model participants

Issue 371
Welcome back to E&O: a subscribers-only weekly-ish newsletter focused on the business, regulation, and effectiveness of health tech.

Oura Points

• • •

Last week I shared some highlights from six years of financial documents that Oura filed with the Finnish government, since news of Oura's confidential IPO filing in the US was making headlines. I dug into annual revenue, marketing spend, P&L, personnel

It's a good one, too.

This article is for Exits & Outcomes subscribers only. Subscribe now to get the weekly newsletter. Enter your email below to subscribe today!

Flo Health’s 2025 revenue, expenses, losses and more.

7.31.26

4 min. Read

Samsung’s ACCESS Model partner. More ACCESS dropouts. Trials.

7.24.26

6 min. Read

CMS proposes to gut RPM/RTM. Thyme revenue. Swing Therapeutics acquired.

7.15.26

6 min. Read

Clinical trials snapshot: OpenEvidence, Hinge, Oura, North Shore Therapeutics, and more

7.10.26

9 min. Read

Hello Heart, Form Health pricing. Headway off the ACCESS Model list

6.26.26

3 min. Read

Six years of Oura’s financials: Revenue, profits, marketing spend and more

5.22.26

4 min. Read

ACCESS Model’s first dropout? Plus: A few new participants

5.08.26

6 min. Read

Are these Utah’s next four AI experiments? Plus: More on the Utah Pharmacy Board’s questions about Doctronic

4.17.26

9 min. Read

Emails show how Doctronic’s AI pilot blindsided Utah’s Medical Board

4.10.26

13 min. Read

Quiet funding rounds. Plus: Digital health-related clinical trial round-ups

3.20.26

5 min. Read